Insmed (INSM) Officer Executes Options, Reports Large 10b5-1 Sales
Rhea-AI Filing Summary
Martina Flammer, M.D., Chief Medical Officer of Insmed Inc. (INSM), reported multiple option exercises and subsequent open-market sales on 09/02/2025 under a 10b5-1 trading plan. The filing shows the exercise of stock options at strike prices ranging from $17.07 to $34.03, converting options into shares (total option exercises listed include 186,943 underlying shares across multiple option grants). Following exercises, the report lists a series of sales on the same date totaling 209,066 shares sold at weighted-average prices between $140.56 and $146.51, with incremental remaining beneficial ownership reported at 83,111 shares after the transactions. The Form 4 notes the 10b5-1 plan was adopted on February 27, 2025, and includes vesting schedules for each option series.
Positive
- Transactions executed under a disclosed 10b5-1 plan (adopted February 27, 2025), providing procedural clarity
- Detailed vesting schedules and option terms are included for each grant, showing exercise/expiration dates
Negative
- Large aggregate sales reported on 09/02/2025 totaling 209,066 shares sold across multiple price ranges
- Significant reduction in beneficial ownership from 269,759 shares before some sales to 83,111 shares after the reported transactions
Insights
TL;DR: Officer exercised multiple option tranches and executed sizable sales under a 10b5-1 plan, resulting in a meaningful reduction in reported holdings.
The filing documents coordinated option exercises and open-market sales executed on 09/02/2025 pursuant to a 10b5-1 plan adopted 02/27/2025. Multiple option grants with strike prices between $17.07 and $34.03 were exercised, and numerous sale blocks were reported at weighted-average prices from $140.56 to $146.51. The sequence leaves the reporting person with 83,111 shares beneficially owned after transactions. From an SEC-disclosure standpoint, the filing is complete: it provides execution dates, option vesting schedules, sale volumes, and weighted-average prices with commitments to provide per-price breakdowns on request.
TL;DR: Insider activity follows a documented Rule 10b5-1 plan and includes standard option-vesting disclosures.
The Form 4 includes the required explanatory notes: adoption date of the 10b5-1 plan, specific vesting schedules for each option grant, and weighted-average sale prices with ranges. Signature and power-of-attorney exhibit are included. The disclosure meets form completeness criteria and clarifies that sales were effected pursuant to the pre-established plan; no additional assertions about motivation or timing are made in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 13,680 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 17,160 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 25,710 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 38,846 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 13,072 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 36,555 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 23,835 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 17,790 | $0.00 | $0.00 |
| Exercise | Common Stock | 13,680 | $34.03 | $466K |
| Exercise | Common Stock | 17,160 | $26.46 | $454K |
| Exercise | Common Stock | 25,710 | $26.43 | $680K |
| Exercise | Common Stock | 38,846 | $17.07 | $663K |
| Exercise | Common Stock | 13,072 | $19.74 | $258K |
| Exercise | Common Stock | 36,555 | $18.95 | $693K |
| Exercise | Common Stock | 23,835 | $29.13 | $694K |
| Exercise | Common Stock | 17,790 | $25.83 | $460K |
| Sale | Common Stock | 19,066 | $141.27 | $2.69M |
| Sale | Common Stock | 5,877 | $142.03 | $835K |
| Sale | Common Stock | 35,245 | $143.16 | $5.05M |
| Sale | Common Stock | 28,063 | $144.05 | $4.04M |
| Sale | Common Stock | 63,782 | $145.33 | $9.27M |
| Sale | Common Stock | 34,615 | $146.05 | $5.06M |
Footnotes (10)
- F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2. This is the weighted average sales price representing 19,066 shares sold at prices ranging from $140.56 to $141.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F3. This is the weighted average sales price representing 5,877 shares sold at prices ranging from $141.61 to $142.55 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F4. This is the weighted average sales price representing 35,245 shares sold at prices ranging from $142.70 to $143.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F5. This is the weighted average sales price representing 28,063 shares sold at prices ranging from $143.70 to $144.63 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F6. This is the weighted average sales price representing 63,782 shares sold at prices ranging from $144.70 to $145.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F7. This is the weighted average sales price representing 34,615 shares sold at prices ranging from $145.70 to $146.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F8. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
- F9. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
- F10. The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the Initial Vesting Date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
